Alzheon Announces Closing Of Oversubscribed $50 Million Series D Financing Round To Accelerate Completion Of Apolloe4 Phase 3 Trial And Expansion Of Product Portfolio
Alzheon Announces Closing Of Oversubscribed $50 Million Series D Financing Round To Accelerate Completion Of Apolloe4 Phase 3 Trial And Expansion Of Product Portfolio
04/14/22, 10:00 AM
Location
framinghamMoney raised
$50 million
Round Type
series d
Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that it has completed an oversubscribed $50 million Series D round from private and institutional investors.
Company Info
Location
framingham, massachusetts, united states
Additional Info
Alzheon, Inc. is a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and other neurodegenerative disorders. We are committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral agent in Phase 3 development as a potentially disease modifying treatment for AD. ALZ-801is an oral small molecule that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. Our clinical expertise and technology platform are focused on developing drug candidates and diagnostic assays using a precision medicine approach based on individual genetic and biomarker information to advance therapies with the greatest impact for patients.